{"id":9578,"date":"2024-08-18T18:49:55","date_gmt":"2024-08-18T18:49:55","guid":{"rendered":"https:\/\/econoasia.com\/lakeshore-biopharma-announces-financial-results-for-fiscal-year-2024\/"},"modified":"2024-08-18T18:49:55","modified_gmt":"2024-08-18T18:49:55","slug":"lakeshore-biopharma-announces-financial-results-for-fiscal-year-2024","status":"publish","type":"post","link":"https:\/\/econoasia.com\/zh-hans\/lakeshore-biopharma-announces-financial-results-for-fiscal-year-2024\/","title":{"rendered":"LakeShore Biopharma Announces Financial Results for Fiscal Year 2024"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2421456\/LakeShore_Bio_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"\/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"prntac\">Gross margin increased to 79.5%; product pipeline continues to advance<\/p>\n<p class=\"prntac\">Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025<\/p>\n<p><span class=\"xn-location\">GAITHERSBURG, Md.<\/span>, <span class=\"xn-chron\">Aug. 15, 2024<\/span> \/PRNewswire\/ \u2014 LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (\u201cLakeShore Biopharma\u201d or the \u201cCompany\u201d), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the fiscal year ended <span class=\"xn-chron\">March 31, 2024<\/span> (\u201cFiscal Year 2024\u201d).<\/p>\n<p>Mr. <span class=\"xn-person\">Dave&#8230;<\/span><\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/portal.sina.com.hk\/finance\/finance-prnewswire\/prnasia\/2024\/08\/15\/937251\/lakeshore-biopharma-announces-financial-results-for-fiscal-year-2024\/\">\u6765\u6e90\u94fe\u63a5<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gross margin increased to 79.5%; product pipeline conti [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[458,1823],"tags":[],"class_list":{"0":"post-9578","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-hong-kong-stock-exchange-sehk","7":"category-hong-kong-stock-exchange-sehk-zh-hans"},"_links":{"self":[{"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/posts\/9578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=9578"}],"version-history":[{"count":0,"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/posts\/9578\/revisions"}],"wp:attachment":[{"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=9578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=9578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/econoasia.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=9578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}